WCI

RI Related News

비회원이 작성한 글입니다!

글작성시 입력했던 비밀번호를 입력해주세요.

List Next Prev
게시글 내용
Imaging trial with SAR-Bombesin in prostate cancer opens for recruitment in Australia
2022/09/08

Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the diagnostic 64Cu SAR-Bombesin trial (BOP) for patients with prostate cancer is open for recruitment in Australia.

 

BOP (Copper-64 SAR Bombesin in PSMA negative Prostate Cancer (BOP) is a Phase II investigator-initiated trial (IIT) in up to 30 patients led by Prof Louise Emmett at St Vincent’s Hospital Sydney. The BOP trial will be assessing the safety of 64Cu-SAR-Bombesin as well as looking at the diagnostic potential for men with negative prostate specific membrane antigen (PSMA) positron emission tomography (PET) or low PSMA expression disease in patients with suspected biochemical recurrence (BCR) of their prostate cancer and patients with metastatic castrate resistant prostate cancer (mCRPC) who are not eligible for PSMA therapy. The trial will be imaging with 64Cu SAR-Bombesin on the day of administration as well as at later timepoints.

 

To read more please visit:

Imaging trial with SAR-Bombesin in prostate cancer opens for recruitment in Australia

Source: clarity